NASA-supported research has led to the development of a cancer treatment that goes from a complex intravenous infusion to a simple subcutaneous injection, after its components showed different behavior in a weightless environment compared to what they are on Earth.
## Skin cancer treatment
This new formulation is likely to be more effective and easier to treat skin cancer, which is largely associated with sun exposure.
In the long-term orbital laboratory aboard the International Space Station, scientists have observed that drug particles grow more uniformly in microgravity conditions. The absence of precipitation and violent rotation of fluid allows the formation of closely sized crystals, preventing separation of components over time, a problem that has limited treatment for years and forced it into slow intravenous administration.
Previous experiments showed that immunotherapy used against multiple cancers formed more regular crystals in the orbit, which made it easier to pass through a fine needle without blockage, provided it remained stable at body temperature. This breakthrough paved the way for transforming orbital knowledge into a practical clinical product.
On September 19, 2025, the US Food and Drug Administration granted approval for the subcutaneous formulation for existing uses, including skin cancer (“melanoma”) after surgery. The new formulation promises to reduce administration time and stress on infusion chambers, while maintaining monitoring requirements for immunological side effects.
Although the treatment does not replace sun protection, the story redefines the role of low-Earth orbit: not just a space for exploration, but a platform that loosens the constraints of medicine, turning laboratory curiosities into tangible cures.
